Formulation, Development & Delivery In-Depth Focus 2020
In this in-depth focus find out about the development of a vaccine regimen to tackle Ebola and how a novel cannabinoid formulation has been developed to treat glioblastoma.
List view / Grid view
Articles
European Pharmaceutical Review Issue 4 2020
Within this issue find articles on the complexities of sterility assurance, how to detect and eliminate the risk of NDMA contamination and the findings from a study involving a novel formulation of cannabinoids that has been developed to treat glioblastoma. Also included are articles on the opportunities blockchain provides for…
Three tips to manufacture quality compliant PPE
Dr Stephane Gobron explores three different ways that manufacturers can use to bring their PPE up to regulatory standard.
Cannabinoid series: a CBD cocrystal for the treatment of PTSD
European Pharmaceutical Review spoke with Dr Andy Yates to discuss Artelo Bioscience’s new CBD and TMP cocrystal, with the potential to treat PTSD.
COVID-19 vaccine: applying healthcare traceability learnings to ensure safe global distribution
Grant Courtney explains why traceability is vital for the current pandemic as it would guarantee that COVID-19 vaccines are safe, effective and suitably distributed.
Post COVID-19: time for drug manufacturers and healthcare providers to rethink their strategies
Mike Owen details how supply chains have been disrupted by COVID-19 and why smart information management can offer a new source of renewed trust.
The Malaysian response to COVID-19: building preparedness for ‘surge capacity’, testing efficiency and containment
A DNDi-commissioned report on the Malaysian reaction to COVID-19 has revealed the strengths and weaknesses of the country’s response.
Why pharma firms would benefit from a modular approach to working with product labelling
According to David Bennett, securing and building trust in the label, brand and process of a highly regulated industry player in a complex age will demand a new approach.
Top 10 biopharma workplaces in the US
A Fortune report reveals the best 10 places to work in the US biopharmaceutical industry.
Is global COVID-19 expertise accessible enough?
Does expert knowledge on COVID-19 need to be more accessible across the globe? This article explores this issue and addresses how greater accessibility could help fight the pandemic in emerging countries.
Trademarks in the medical sphere: practice, examination and obstacles for registration in Russia, Ukraine and the CIS
Dr Tatiana Lipovaya and Alyona Chernoknyzhnaya discuss some of the main considerations when applying for trademarks in the pharmaceutical industry in Russia, Ukraine and the CIS.
Effect of COVID-19 on treatment of non-communicable diseases
Coronavirus or COVID-19 is currently the leading cause of mortality worldwide. With a patient database of 4,150,343 active cases (as of 28 June 2020), it is the most hit word on the internet today. Besides this catastrophe, the world has been facing a severe shortage of healthcare facilities, which has…
Outsourcing update: the latest developments in pharma
European Pharmaceutical Review explores some of the latest developments in outsourcing, including clinical development and production agreements; acquisitions and collaborations; and expansions.
FMD alerts in 2020 – where we are a year into legislation
Over a year since the EU FMD came into force, false alerts remain a problem preventing the realisation of the full benefits of the directive. Grant Courtney examines the reasons behind these alerts occurring and looks at the action stakeholders must now take.
Biosimilar uptake will take more than competitive pricing
This article explores what pharmaceutical companies could be doing to promote injectable biosimilar approval and consumer uptake.
